Drug reference

Ramucirumab

Monoclonal Antibody · Antineoplastic

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AbciximabSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter
AlteplaseSevereDatabaseDDInter
AnagrelideSevereDatabaseDDInter

Mechanism

Ramucirumab is a human IgG1 monoclonal antibody that selectively binds to the vascular endothelial growth factor receptor-2 (VEGFR-2). This binding prevents the attachment of VEGF-A, VEGF-C, and VEGF-D ligands to VEGFR-2, thereby inhibiting VEGF-induced angiogenesis. It also inhibits tumor vascular permeability and enhances tumor blood flow and drug delivery.

Indications

Treatment of advanced gastric cancer or gastro-oesophageal junction adenocarcinoma, in combination with paclitaxel, in patients with disease progression after prior platinum and fluoropyrimidine chemotherapy.Treatment of advanced gastric cancer or gastro-oesophageal junction adenocarcinoma, as monotherapy, in patients with disease progression after prior platinum or fluoropyrimidine chemotherapy, and for whom treatment in combination with paclitaxel is not appropriate.Treatment of metastatic colorectal cancer, in combination with FOLFIRI (irinotecan, fluorouracil and folinic acid), in patients with disease progression on, or after, prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Treatment of non-small cell lung cancer.metastatic colorectal cancer (mCRC) with disease progression on or after prior therapyadvanced gastric adenocarcinoma (single agent or in combination with paclitaxel) with disease progression on or after prior chemotherapymetastatic NSCLC (in combination with docetaxel) with disease progression on or after chemotherapy

Dosing

Adult: BY INTRAVENOUS INFUSION: For advanced gastric cancer or gastro-oesophageal junction adenocarcinoma, in combination with paclitaxel: 8 mg/kg on days 1 and 15 of a 28-day cycle, administered prior to paclitaxel infusion. For advanced gastric cancer or gastro-oesophageal junction adenocarcinoma, as monotherapy: 8 mg/kg every 2 weeks.…